JP2010512747A5 - - Google Patents

Download PDF

Info

Publication number
JP2010512747A5
JP2010512747A5 JP2009541384A JP2009541384A JP2010512747A5 JP 2010512747 A5 JP2010512747 A5 JP 2010512747A5 JP 2009541384 A JP2009541384 A JP 2009541384A JP 2009541384 A JP2009541384 A JP 2009541384A JP 2010512747 A5 JP2010512747 A5 JP 2010512747A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
isolated nucleic
seq
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009541384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512747A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/025535 external-priority patent/WO2008076324A2/en
Publication of JP2010512747A publication Critical patent/JP2010512747A/ja
Publication of JP2010512747A5 publication Critical patent/JP2010512747A5/ja
Withdrawn legal-status Critical Current

Links

JP2009541384A 2006-12-14 2007-12-13 筋疾患および心臓血管障害を処置するための組成物および方法 Withdrawn JP2010512747A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86993706P 2006-12-14 2006-12-14
PCT/US2007/025535 WO2008076324A2 (en) 2006-12-14 2007-12-13 Compositions and methods to treat muscular & cardiovascular disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011178297A Division JP2012019789A (ja) 2006-12-14 2011-08-17 筋疾患および心臓血管障害を処置するための組成物および方法
JP2012034691A Division JP2012131812A (ja) 2006-12-14 2012-02-21 筋疾患および心臓血管障害を処置するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2010512747A JP2010512747A (ja) 2010-04-30
JP2010512747A5 true JP2010512747A5 (enExample) 2011-02-03

Family

ID=39536897

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009541384A Withdrawn JP2010512747A (ja) 2006-12-14 2007-12-13 筋疾患および心臓血管障害を処置するための組成物および方法
JP2011178297A Withdrawn JP2012019789A (ja) 2006-12-14 2011-08-17 筋疾患および心臓血管障害を処置するための組成物および方法
JP2012034691A Withdrawn JP2012131812A (ja) 2006-12-14 2012-02-21 筋疾患および心臓血管障害を処置するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011178297A Withdrawn JP2012019789A (ja) 2006-12-14 2011-08-17 筋疾患および心臓血管障害を処置するための組成物および方法
JP2012034691A Withdrawn JP2012131812A (ja) 2006-12-14 2012-02-21 筋疾患および心臓血管障害を処置するための組成物および方法

Country Status (11)

Country Link
US (3) US20100280094A1 (enExample)
EP (1) EP2104733A2 (enExample)
JP (3) JP2010512747A (enExample)
KR (1) KR20090098818A (enExample)
CN (2) CN102604951A (enExample)
AU (1) AU2007334502B2 (enExample)
BR (1) BRPI0719995A2 (enExample)
CA (1) CA2672606A1 (enExample)
EA (2) EA201101361A1 (enExample)
MX (1) MX2009006310A (enExample)
WO (1) WO2008076324A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2397439T3 (es) 2006-08-01 2013-03-07 Board Of Regents Of The University Of Texas System Identificación de un microARN que activa la expresión de la cadena pesada beta de la miosina
US8481507B2 (en) * 2007-07-31 2013-07-09 The Board Of Regents, The University Of Texas System Micro-RNAs that control myosin expression and myofiber identity
MX2011008190A (es) * 2009-02-04 2011-10-06 Univ Texas Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease
EP2703501A1 (en) * 2009-03-12 2014-03-05 Brandeis University Reagents and Methods for PCR
CN103380215A (zh) 2010-12-15 2013-10-30 米拉根医疗公司 包含锁定核苷酸的微rna抑制剂
JP6177243B2 (ja) 2011-10-06 2017-08-09 ミラゲン セラピューティクス, インコーポレイテッド マイクロrnaの調節による全身エネルギーホメオスタシスの制御
DK3354734T3 (da) 2012-06-21 2020-06-29 Miragen Therapeutics Inc Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster
US10443052B2 (en) * 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
US9637738B2 (en) * 2013-04-10 2017-05-02 Reveragen Biopharma, Inc. Methods and agents to increase therapeutic dystrophin expression in muscle
MX2016004651A (es) 2013-10-11 2016-08-05 Ionis Pharmaceuticals Inc Composiciones para modular la expresion de c9orf72.
WO2016022536A2 (en) * 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
EP3722424A1 (en) 2015-04-16 2020-10-14 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
CN106148519A (zh) * 2016-07-05 2016-11-23 无锡市第二人民医院 一种microRNA‑499的快速检测方法
WO2019014656A1 (en) 2017-07-14 2019-01-17 Han Si Ping METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
CN111630166B (zh) * 2017-08-10 2024-04-19 希望之城 条件性-siRNA及其在治疗心肌肥大中的用途
KR102281710B1 (ko) 2021-02-19 2021-07-28 조기정 에어튜브를 이용한 선박 안전장치
CN119246849B (zh) * 2024-12-09 2025-03-14 上海基灵生物科技有限公司 一种检测犬心脏损伤的试剂盒及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
ES2083593T3 (es) * 1990-08-03 1996-04-16 Sterling Winthrop Inc Compuestos y metodos para inhibir la expresion de genes.
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
JP3516167B2 (ja) * 1992-12-08 2004-04-05 ローム株式会社 タンタルコンデンサチップの製造方法
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
CN101291653B (zh) * 2003-07-16 2012-06-27 普洛体维生物治疗公司 脂质包封的干扰rna
WO2005021800A2 (en) * 2003-08-22 2005-03-10 Sirna Therapeutics, Inc. Detection and quantitation of nucleic acid molecules in biological samples
EP2322650A1 (en) * 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
US8592384B2 (en) * 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
US20070092882A1 (en) * 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
ES2612903T3 (es) * 2006-01-10 2017-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Moléculas de ácido nucleico y colecciones de las mismas, su aplicación e identificación
ES2397439T3 (es) * 2006-08-01 2013-03-07 Board Of Regents Of The University Of Texas System Identificación de un microARN que activa la expresión de la cadena pesada beta de la miosina
US8481507B2 (en) * 2007-07-31 2013-07-09 The Board Of Regents, The University Of Texas System Micro-RNAs that control myosin expression and myofiber identity

Similar Documents

Publication Publication Date Title
JP2010512747A5 (enExample)
DK3222724T3 (en) ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES
JP2015502365A5 (enExample)
JP2005517427A5 (enExample)
JP2013535212A5 (enExample)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
JP2014527401A5 (enExample)
JP2013510561A5 (enExample)
JP2005517438A5 (enExample)
BRPI0811170B8 (pt) oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
JP2005517432A5 (enExample)
JP2009524419A5 (enExample)
JP2008283975A5 (enExample)
JP2012050438A5 (enExample)
JP2010530239A5 (enExample)
JP2005517452A5 (enExample)
JP2012504389A (ja) 修飾を有するdsRNAによる遺伝子発現の特異的な阻害のための組成物および方法
JP2009532392A5 (enExample)
JP2005517436A5 (enExample)
JP2010532163A5 (enExample)
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
CN104388427A (zh) miRNA-200b在制备β-catenin抑制剂的新用途
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
JP2006502243A5 (enExample)
WO2013013165A2 (en) Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus